Geert DʼHaens Selected Research

Crohn Disease (Crohn's Disease)

1/2018	Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
3/2015	Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Geert DʼHaens Research Topics

Disease

2	Crohn Disease (Crohn's Disease) 01/2018 - 03/2015
1	Lymphoma (Lymphomas) 01/2018

Drug/Important Bio-Agent (IBA)

1	Adalimumab (Humira)FDA Link 01/2018
1	2-mercaptopurineIBA 01/2018
1	Infliximab (Remicade)FDA Link 03/2015
1	Biomarkers (Surrogate Marker)IBA 03/2015
1	NucleotidesIBA 03/2015
1	Thioguanine (Tioguanine)FDA Link 03/2015
1	Azathioprine (Imuran)FDA LinkGeneric 03/2015

Therapy/Procedure

1	Therapeutics 03/2015